- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer -
- Preliminary Data from Moffitt NSCLC Study to be Presented at the Upcoming 19th
“The start of patient dosing in the study at MD Anderson allows for exploration of TIL as a platform for treatment of multiple new solid tumors. Furthermore, this targeted patient population is left with very few treatment options and therefore is an unmet medical need. We are extremely pleased to be collaborating with MD Anderson as we investigate the potential of LN-145 to treat these patients with sarcomas and ovarian cancer,” said Dr.
The first MD Anderson study will enroll up to 54 patients. The endpoints for the trial are safety and efficacy of Iovance-manufactured LN-145 for the treatment of patients with soft tissue sarcoma, osteosarcoma and platinum-resistant ovarian cancer. The trial utilizes Iovance’s Gen 2 manufacturing process. A second clinical study is also in start-up under the collaboration using TIL manufactured by MD Anderson and using urelumab as a co-stimulatory agent during the manufacturing process. Additional information on this study is available at www.clinicaltrials.gov using the identifier number NCT03610490.
The ongoing investigator-sponsored study in NSCLC is currently underway in collaboration with Moffitt, Stand Up To Cancer, and other collaborators and is designed to allow dosing of the combination of TIL manufactured by Moffitt and nivolumab in NSCLC patients. An abstract titled, Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC, has been accepted for presentation at the upcoming WCLC. The full details of the presentation are expected to be released in September. Additional information on this study is available at www.clinicaltrials.gov using the identifier number NCT03215810.
About
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding clinical trials for NSCLC, soft tissue sarcoma, osteosarcoma and platinum-resistant ovarian cancer are examples of such forward-looking statements. The forward-looking statements include, but are not limited to, risks and uncertainties relating to the success, timing, projected enrollment, dosing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company-sponsored and collaborator-sponsored trials), such as statements regarding the timing of initiation and completion of these trials; the timing of and our or our collaborator’s ability to obtain and maintain
Investor Relations Contact:
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Contact:
212-850-5705
john.capodanno@fticonsulting.com